See the DrugPatentWatch profile for brilinta
What is Brilinta?
Brilinta, also known by its generic name ticagrelor, is an antiplatelet medication used to prevent blood clots in individuals who have experienced a heart attack or have certain other cardiovascular conditions [1]. It works by inhibiting the P2Y12 receptor on platelets, reducing their ability to aggregate and form clots [2].
When does Brilinta's patent expire?
The patent protection for Brilinta is complex, with multiple patents covering different aspects of the drug and its use. Information on specific patent expiry dates is often dynamic due to patent challenges and extensions. For detailed and up-to-date patent information, DrugPatentWatch.com is a valuable resource [3].
Are there generic versions of Brilinta available?
As of recent information, there are generic versions of ticagrelor available in the market [1]. The availability of generics typically follows the expiry or successful challenge of primary patents.
How do generic Brilinta drugs compare to the brand name?
Generic versions of ticagrelor are bioequivalent to the brand-name Brilinta. This means they contain the same active ingredient, ticagrelor, and are absorbed into the body at the same rate and to the same extent. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), require generic drugs to meet the same standards for safety, efficacy, and quality as their brand-name counterparts [4].
What are the potential risks of taking ticagrelor?
The primary risks associated with ticagrelor include bleeding, which can range from minor bruising to severe and life-threatening hemorrhages [1][2]. Other potential side effects can include shortness of breath, dizziness, and gastrointestinal issues. Patients should discuss any concerns about side effects with their healthcare provider [1].
Who manufactures generic ticagrelor?
Multiple pharmaceutical companies manufacture generic versions of ticagrelor. The specific manufacturers can vary by region and availability.
Sources:
[1] https://www.drugpatentwatch.com/drug/brilinta
[2] https://www.drugpatentwatch.com/search/ticagrelor
[3] https://www.drugpatentwatch.com/
[4] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-oder/generics